Latest Industry Insights
Exploiting Bacteriophage as a Diagnostic Tool
Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.
Targeting EBV-Infected Cells To Treat Multiple Sclerosis
Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.
Leveraging the T-Cell Response to Epstein-Barr Virus To Treat Life-Threatening Diseases
Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.
Women in Science: Perspectives From Industry
In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.
Targeting the Gut Microbiome To Understand Age-Related Cognitive Decline
In this interview, we speak to Dr. Antal Szalay, CEO of Ultimate Medicine, about how his company helped establish that a microbiome metabolite can cause age-related memory loss.
Designing Antibody-Based Therapeutics for Autoimmune Disorders
Therapies are needed for patients with autoimmune disorders such as lupus. Technology Networks spoke to Cherie Ng, the senior director for research at Equillium, about how the first-in-class anti-CD6 therapy was designed.
Gene-Edited Stem Cell-Derived Therapies – A Functional Cure for T1D?
Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.
2022: The Year We Implement COVID-19 Lessons Into Practice
As we seek a better tomorrow, here are three predictions from global life science and diagnostics company, PerkinElmer, that will lead to better health outcomes.
Raising the Bar in Proteomics
How do we continue to push the boundaries in analytical capabilities, increase confidence in results and apply MS to a wider range of research questions? Technology Networks posed these questions to Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, in a recent interview.
Developing Temperature-Stable ADDomer Vaccines for Untreatable Diseases
Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.